CLX

Business profile & competitive position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry. It manufactures and markets consumer and professional products under brands including Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional arm sells Purell, CloroxPro, and Clorox Healthcare. In fiscal 2026 it generated roughly $6.7 billion in net sales, employed about 9,200 people, operated in approximately 25 countries, and sold into about 95 markets. The April 2026 completion of the GOJO Industries acquisition added hand-hygiene assets and deepened the company’s business-to-business health and hygiene footprint.

Portfolio breadth and shelf presence are the most tangible competitive supports in the data. The brand roster spans cleaning, food, bags and wraps, and personal care, giving the company a diversified revenue mix inside the staples aisle. Distribution, however, is heavily concentrated: Walmart alone accounted for 26% of consolidated fiscal 2026 net sales, and the five largest customers represented about half. That concentration is a source of pricing and negotiation leverage for retailers and a structural risk factor for Clorox.

Profitability is positive but not outsized. The 8.7% net margin is consistent with a mature packaged-goods business, yet it does not point to a wide, cost-driven moat. The reported return on equity of -1,893.5% is extreme and almost certainly reflects a deeply negative shareholders’ equity base rather than an operational loss, because the company is profitable and trades at a P/E of 17.8. In practice, thatROE profile usually signals heavy leverage, share buybacks, or cumulative losses that have eroded book equity, so it is more a balance-sheet artifact than a measure of competitive advantage.

Financial posture

Clorox currently carries a $10.3 billion market capitalization and trades at roughly $85.56, with a trailing P/E of 17.8 and a low beta of 0.57. The beta fits the Consumer Defensive label: the stock has historically moved less than the broad market, which is typical for a staples business with recurring-demand products. At the same time, the current price sits below the 50-day exponential moving average of $89.05, while the RSI is 48.3, a neutral reading.

The 8.7% net margin shows the company converts sales into profit, and the 17.8 P/E suggests the market is not pricing it for rapid growth. The glaring outlier remains the -1,893.5% ROE. Because Clorox is profitable, the figure points to a negative book-value position rather than negative earnings. That implies a leveraged capital structure or a long history of capital returns exceeding cumulative income. Investors evaluating the stock should treat ROE here as a solvency and capital-structure signal rather than as a profitability scorecard. No debt figures were supplied, but the scale of the negative ROE alone suggests the balance sheet carries more leverage than the headline P/E implies.

Strategic priorities & outlook

The company’s most recent 10-K describes a business working through a transition year. Fiscal 2026 saw declines in organic sales and earnings, with diluted EPS down 26%. Part of that drop came from macroeconomic headwinds, and part came from ERP-transition timing that had pulled some sales forward into fiscal 2025.

Near-term priorities are organized around the IGNITE strategy, which has four stated choices: fuel long-term profitable growth, innovate consumer experiences, reimagine how the company and its people work, and continuously evolve the product portfolio. Operationally, management is focused on completing and optimizing a new enterprise resource planning system and broader digital transformation, aiming for long-term efficiencies across supply chain, digital commerce, innovation, and brand building. It also plans to invest in strong brands, strategic digital capabilities, and a streamlined operating model to build what it calls a more resilient company.

The GOJO integration is a concrete part of that plan. Beyond the consumer shelf, Clorox wants to expand in health and hygiene, grow professional and institutional markets, and optimize the portfolio. Another material event in fiscal 2026 was the expiration of the Glad bags and wraps venture with Procter & Gamble on January 31, 2026, after which Clorox purchased P&G’s 20% interest and retained core intellectual property licenses on a royalty-free basis. That move simplifies ownership of a key brand but also removes a partner that had helped carry it.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox sits in a sector that is generally considered recession-resistant because consumers still buy bleach, trash bags, cat litter, and salad dressing during downturns. That defensive quality is one reason the beta is only 0.57. Still, the industry is not immune to macro pressures.

Input cost exposure is real. Resin for trash bags, agricultural commodities for food products, chemicals for disinfectants, and energy for manufacturing and transportation can all move with commodity cycles and currency markets. Trade policy matters too: tariffs on imported raw materials or packaging can compress margins, and because Clorox operates in roughly 25 countries and sells in about 95 markets, foreign-exchange translation can add volatility to reported results.

Regulatory risk is another sector hallmark. Cleaning, disinfecting, and healthcare-adjacent products face oversight from agencies such as the EPA and, for some health and hygiene items, the FDA. Changes in chemical safety rules, labeling requirements, or sustainability mandates can raise compliance costs or force formula changes. Finally, the industry’s heavy reliance on a few large retailers means that pricing power is never entirely independent of the bargaining leverage at Walmart and other top customers.

Recent developments

The latest headlines around the ticker are light on company-specific news but supportive of the dividend and institutional-holding narrative. On October 19, 2026, Seeking Alpha included Clorox among “5 Dividend Growth Stocks With Yields Up To 7.99%,” while on the same day Zacks published a note on Procter & Gamble’s innovation push as a catalyst for long-term growth. Also on October 19, Defenseworld reported that the State of Alaska Department of Revenue increased its Clorox holdings. A day earlier, on October 18, 2026, The Motley Fool listed Clorox among “5 Dividend Stocks Trading Near 52-Week Lows That I’d Hold for the Next 5 Years.”

Those items line up with the current price action: the stock is trading near its 52-week low area, below its 50-day EMA of $89.05, and is being discussed as a dividend-oriented holding rather than a growth story. The Alaska holding increase is a small institutional flow signal, not a fundamental change, but it shows at least one public fund adding shares at these levels.

Earnings behavior & post-earnings drift

Clorox has beaten earnings expectations in six of the last eight reported quarters, a 75% beat rate, with an average earnings surprise of 9.6%. The average five-day price move in the sessions following those reports has been +1.67%, classified as an upward drift. That said, the average masks large individual swings, and the stock has not rewarded beats consistently.

Looking at the last four reports, most recent first, the pattern is mixed. On August 3, 2026, Clorox reported $1.66 versus an estimate of $1.64, a 1.2% beat; the stock rose 6.52% the next day and 9.61% over the following five days. On April 30, 2026, the company delivered $1.64 against $1.55, a 5.8% beat, yet the stock fell 9.67% the next day and 4.49% over five days. On February 3, 2026, it missed by 2.8% with $1.39 versus $1.43, but the stock still rose 2.43% the next day and 5.63% over five days. On November 3, 2025, Clorox beat by 3.9% with $0.85 versus $0.818, rose 1.17% the next day, then drifted down 4.08% over the following five sessions.

The next report is scheduled for November 2, 2026, after the market close, with the market’s real expectation at $1.07. The historical beat rate and the 9.6% average surprise suggest Clorox often exceeds that estimate by a meaningful margin, but the post-report price action has been volatile enough that the options market and short-term traders should treat even a beat as an event that can go either way.

For a deeper dive into how sell-side and institutional models are currently framing Clorox after the GOJO integration, the ERP rollout, and the fiscal 2026 margin reset, readers should review the full institutional verdict and consensus summary rather than relying on headline figures alone.